Edition:
United States

Neovacs SA (ALNEV.PA)

ALNEV.PA on Paris Stock Exchange

0.88EUR
10:12am EDT
Change (% chg)

€0.00 (+0.00%)
Prev Close
€0.88
Open
€0.88
Day's High
€0.89
Day's Low
€0.87
Volume
100,438
Avg. Vol
619,249
52-wk High
€1.17
52-wk Low
€0.66

Latest Key Developments (Source: Significant Developments)

Neovacs FY operating loss widens to 17.3‍​ million euros
Thursday, 30 Mar 2017 11:45am EDT 

Neovacs SA : FY revenue ‍​0.4 million euros versus 1.2 million euros ($1.29 million) year ago . FY operating loss of 17.3‍​ million euros versus loss of 11.3 million euros year ago .FY net loss of ‍​13.9 million euros versus loss of 4.7 million euros year ago.  Full Article

Neovacs and Biosense sign option agreement worth up to €65 million plus royalties
Tuesday, 21 Feb 2017 08:00am EST 

Neovacs SA : Neovacs and Biosense sign option agreement worth up to €65 million plus royalties for Chinese development and commercial rights to ifnα kinoid for lupus and dermatomyositis . Neovacs SA - Neovacs receives an upfront fee and is eligible for additional milestone payments and double-digit sales royalties . Neovacs SA - Biosense receives option for development, commercial rights to ifnα kinoid for lupus and dermatomyositis in China, other selected territories . Neovacs SA - upon completion of Neovacs' ongoing Phase IIB trial for ifnα kinoid in lupus biosense will receive commercial rights for ifnα kinoid . Neovacs SA - Biosense will fund a Phase III clinical trial for ifnα kinoid in China . Neovacs SA - Biosense will bear all costs associated with these development and regulatory-related initiatives . Neovacs SA - Biosense receives first right of refusal in agreed upon asian markets for any further ifnα kinoid indications, including type 1 diabetes .Neovacs SA - additional terms were not disclosed.  Full Article

Neovacs and Biosense sign option agreement worth up to 65 million euros
Tuesday, 21 Feb 2017 01:30am EST 

Neovacs SA : And biosense sign option agreement worth up to 65 million euros ($68.80 million) plus royalties for Chinese development and commercial rights to Ifnalpha Kinoid for lupus and dermatomyositis . Receives an upfront fee and is eligible for additional milestone payments and double digit sales royalties .Receives option for development and commercial rights to Ifnalpha Kinoid for lupus and dermatomyositis in China and other selected territories.  Full Article

Neovacs issued new broad patent in China for IFNalpha Kinoid
Thursday, 9 Feb 2017 02:06am EST 

Neovacs SA : Announced today that it has received notification of a new patent from the Chinese patent office . Issued new broad patent in China for IFNalpha Kinoid .Patent is valid until at least 2032.  Full Article

Neovacs obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE)
Wednesday, 7 Dec 2016 01:00am EST 

Neovacs SA : Neovacs is currently enrolling patients in an international phase IIb trial (IFN-K 002) in Lupus (SLE) .This study, which has already recruited more than half of its targeted 178 patients, is underway in 21 countries in Europe, Asia, Latin America and US.  Full Article

Neovacs announces cooperation agreement with the immunology of diabetes department at the Paris Cochin hospital
Wednesday, 12 Oct 2016 01:35am EDT 

Neovacs SA : Cooperation agreement with the immunology of diabetes department at the Paris Cochin hospital .The objective of this agreement is to achieve proof of concept for IFNa Kinoid in type 1 diabetes.  Full Article

Neovacs H1 net loss widens to 6.8 mln euros
Friday, 30 Sep 2016 11:45am EDT 

Neovacs SA : H1 net loss is 6.8 million euros ($7.6 million) versus a loss of 4.9 million euros a year ago . H1 operating loss is 7.9 million euros versus a loss of 5.6 million euros a year ago . H1 revenue is 104,000 euros versus 94,000 euros a year ago .Neovacs will present at attend bio europe 2016 to be held in cologne November 7-9.  Full Article

Neovacs and Stellar Biotechnologies launch Neostell, joint venture to manufacture Kinoids
Tuesday, 19 Jul 2016 02:01am EDT 

Neovacs SA : Neovacs and Stellar Biotechnologies announce launch of Neostell, joint venture to manufacture Kinoids .Bernard Fanget, Frank Oakes and Miguel Sieler appointed to administrative board.  Full Article

Neovacs raises 8 million euros in capital increase
Thursday, 23 Jun 2016 01:35am EDT 

Neovacs SA : Said on Wednesday it raised 8 million euros ($9.1 million) in capital increase .Totality of offered shares have been subscribed.  Full Article

Neovacs launches capital increase of 8 million euros
Wednesday, 1 Jun 2016 01:36am EDT 

Neovacs SA : Launches a capital increase of 8 million euros ($8.90 million) with preferential subscription rights . Subscription period: 2 to 15 June 2016 . Subscription price: 0.85 euro per share .Subscription ratio: 2 new shares for 7 existing shares.  Full Article

More From Around the Web

BRIEF-Neovacs to present clinical development update on ifnalpha kinoid in dermatomyosis

* Reg-Neovacs to present clinical development update on ifnalpha kinoid in dermatomyosis